Boston Partners Exelixis, Inc. Transaction History

Boston Partners

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 13, 2020	SELL	$14.46 - $21.8 $1.43 Million - $2.16 Million	-99,229 Closed	0 $0
Q4 2019 Feb 05, 2020	SELL	$15.15 - $18.89 $542,506 - $676,432	-35,809 Reduced 26.52%	99,229 $1.75 Million
Q3 2019 Nov 20, 2019	SELL	$17.68 - $22.65 $45,932 - $58,844	-2,598 Reduced 1.89%	135,038 $2.39 Million
Q2 2019 Aug 09, 2019	SELL	$18.93 - $24.75 $363,172 - $474,828	-19,185 Reduced 12.23%	137,636 $2.94 Million
Q1 2019 May 03, 2019	SELL	$19.6 - $24.76 $189,336 - $239,181	-9,660 Reduced 5.8%	156,821 $3.73 Million
Q4 2018 Feb 07, 2019	BUY	$13.65 - $21.8 $2.27 Million - $3.63 Million	166,481 New	166,481 $3.28 Million

529

244M

2.84M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.8B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Boston Partners, based on Form 13F filings with the SEC.

Stay updated on Boston Partners with notifications on news.